4286-99-1 Usage
Uses
Used in Pharmaceutical Development:
CHEMBRDG-BB 7119439 is used as a research compound for the development of new pharmaceuticals targeting the inhibition of calpain enzyme. This is crucial for exploring its potential in treating various medical conditions.
Used in Neurodegenerative Disease Treatment:
CHEMBRDG-BB 7119439 is used as a therapeutic agent for neurodegenerative diseases, where its calpain inhibitory properties may help in managing the progression of these conditions.
Used in Cancer Therapy:
In the field of oncology, CHEMBRDG-BB 7119439 is used as a potential treatment option, leveraging its ability to inhibit calpain, which may play a role in controlling cancer progression and metastasis.
Used in Cardiovascular Disorder Management:
CHEMBRDG-BB 7119439 is used as a pharmaceutical agent for managing cardiovascular disorders, with the hypothesis that calpain inhibition could provide benefits in treating such conditions.
The applications of CHEMBRDG-BB 7119439 are currently under investigation, and its uses will be more clearly defined as research progresses and clinical trials provide further insights into its efficacy and safety.
Check Digit Verification of cas no
The CAS Registry Mumber 4286-99-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,2,8 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 4286-99:
(6*4)+(5*2)+(4*8)+(3*6)+(2*9)+(1*9)=111
111 % 10 = 1
So 4286-99-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H8Cl2O3/c10-4-6-3-7(11)1-2-8(6)14-5-9(12)13/h1-3H,4-5H2,(H,12,13)
4286-99-1Relevant academic research and scientific papers
Route development and bulk synthesis of CP-865,569
Belecki, Katherine,Berliner, Martin,Bibart, Richard Todd,Meltz, Cliff,Ng, Karl,Phillips, James,Ripin, David H. Brown,Vetelino, Michael
, p. 754 - 761 (2012/12/29)
The synthesis of zwitterionic CP-865,569 by three different synthetic routes is described. The first two routes differ in the method of introducing the sulfonic acid at the penultimate step: by sulfite displacement of a benzylic chloride and by oxidation of a benzylic thioacetate. The third route is a convergent route to the drug candidate. The synthesis strategy was primarily driven by the need to introduce the sulfonic acid functionality at the final stage of the synthesis due to the high water solubility and low organic solubility of the desired product.
